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Background/introduction
High Intensity Focused Ultrasound (HIFU) is a non-inva-
sive treatment for localized prostate cancer. The purpose
of this study was to investigate the safety and effectiveness
of HIFU as a monotherapy for the initial treatment of low-
risk prostate cancer (PCa) in the United States.
Methods
An Investigational Device Exemption trial received local
IRB approval at thirteen sites in the United States and
Canada. Subjects with untreated low-risk localized PCa
were recruited and treated with single session mono-
therapy HIFU without adjuvant TURP or hormone abla-
tion. Repeat HIFU procedures were not permitted.
Subjects were followed at 1 and 3 months and every
three months thereafter. The primary endpoint was
24 month biochemical freedom from failure (the “Phoe-
nix” definition). Subjects underwent biopsy for cause
(rising PSA) or at the end of study (24 months). Adverse
events were assessed at each postoperative visit and
reported as mild, moderate or severe and related to the
device or procedure at 24 months.
Results and conclusions
A total of 135 subjects were prospectively enrolled. Mean
age and PSA at treatment (± SD) was 64.1 ± 6.7 years
and 4.6 ± 2.4 ng/ml, respectively. The Gleason grade and
stage were 6 and T1c for 97% and 81% of subjects,
respectively. A PSA nadir < 0.5 ng/ml was achieved in
74.1% of subjects. The primary biochemical endpoint was
achieved by 90.5% (95% CI: 85.2% - 95.8%) of subjects.
Freedom from positive biopsy was 97/135 (72%) at two
years. The erectile dysfunction rate was 38%, urinary
incontinence: 3%, urinary retention: 3% and stricture: 1%.
No fistulae were observed. Both the local (biopsy) control
and the biochemical survival rates are promising follow-
ing HIFU which was utilized as a single session mono-
therapy without any adjuvants. The adverse event profile
demonstrates promising erectile function preservation
and low rates of long term morbidity. These results com-
plement published long term outcomes from Europe,
where HIFU is utilized in combination therapy, in repeat
treatments, and as salvage treatment. Results from this
study show that HIFU appears to be a safe and efficacious
primary therapy for localized prostate cancer.
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